We are live on
!
Find out more
DTC
Deep Track Capital Portfolio holdings
AUM
$6.87B
1-Year Est. Return
205.24%
This Fund
S&P 500
This Quarter
Est. Return
+3.27%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
–
Cap. Flow
+$1.41B
Cap. Flow
% of AUM
99.82%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
55
New
55
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$69M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$65.7M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$65.6M |
| 4 |
Keros Therapeutics
KROS
|
+$64.8M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$62M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.41% |
| 2 | Miscellaneous | 4.49% |
| 3 | Real Estate | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TCDA
26
DELISTED
Tricida, Inc. Common Stock
TCDA
| $22.3M | 1.58% |
+2,335,143
| New | +$15.1M |
|
27
Dianthus Therapeutics
DNTH
$5.83B
| $21.6M | 1.52% |
+304,375
| New | +$30.6M |
|
|
SAGE
28
DELISTED
Sage Therapeutics
SAGE
| $21.3M | 1.5% |
+500,000
| New | +$20.9M |
|
29
Passage Bio
PASG
$15.4M
| $20.4M | 1.44% |
+160,850
| New | +$26.3M |
|
|
KALV
30
DELISTED
KalVista Pharmaceuticals
KALV
| $19.8M | 1.4% |
+1,500,000
| New | +$23.9M |
|
31
Nkarta
NKTX
$207M
| $19.4M | 1.37% |
+1,264,426
| New | +$21.7M |
|
|
VERV
32
DELISTED
Verve Therapeutics
VERV
| $18.4M | 1.3% |
+500,000
| New | +$21M |
|
|
KRTX
33
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $17.1M | 1.2% |
+130,200
| New | +$16.8M |
|
|
SAGE
34
CALL
DELISTED
Sage Therapeutics
SAGE
| $17M | 1.2% |
+400,000
| New | +$16.7M |
|
35
Tenaya Therapeutics
TNYA
$149M
| $14.4M | 1.02% |
+762,317
| New | +$16.6M |
|
36
Protagonist Therapeutics
PTGX
$9.3B
| $14.4M | 1.02% |
+421,660
| New | +$13.3M |
|
37
Fulcrum Therapeutics
FULC
$291M
| $13.3M | 0.94% |
+750,000
| New | +$14.9M |
|
|
SRRA
38
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $13.2M | 0.93% |
+607,600
| New | +$13.4M |
|
39
Acumen Pharmaceuticals
ABOS
$205M
| $13.1M | 0.92% |
+1,933,040
| New | +$21.2M |
|
40
Atara Biotherapeutics
ATRA
$99.1M
| $11.8M | 0.83% |
+30,000
| New | +$12.6M |
|
41
GH Research
GHRS
$1.9B
| $11.7M | 0.82% |
+499,400
| New | +$11M |
|
42
Ascendis Pharma A/S
ASND
$16.2B
| $10.8M | 0.76% |
+80,000
| New | +$11.9M |
|
|
ATYR
43
aTyr Pharma
ATYR
$37.5M
| $8.22M | 0.58% |
+1,100,000
| New | +$9.18M |
|
44
CALL
Vanda Pharmaceuticals
VNDA
$302M
| $7.84M | 0.55% |
+500,000
| New | +$8.71M |
|
|
45
Vanda Pharmaceuticals
VNDA
$302M
| $7.84M | 0.55% |
+500,000
| New | +$8.71M |
|
46
Assembly Biosciences
ASMB
$536M
| $6.99M | 0.49% |
+250,000
| New | +$8.2M |
|
47
PUT
Nektar Therapeutics
NKTR
$2.28B
| $6.75M | 0.48% |
+33,333
| New | +$7.23M |
|
48
CALL
BridgeBio Pharma
BBIO
$13.4B
| $6.67M | 0.47% |
+400,000
| New | +$16.9M |
|
|
CNTA
49
DELISTED
Centessa Pharmaceuticals
CNTA
| $4.5M | 0.32% |
+400,000
| New | +$5.38M |
|
|
TECX
50
Tectonic Therapeutic
TECX
$561M
| $4.04M | 0.29% |
+87,511
| New | +$5.03M |
|
Similar funds
PFS
EWM
NP
NPT
RCWMU
CA
LIP
CI
Deep Track Capital's Q4 2021 Portfolio in Review
Q4 2021 is the first quarter with a 13F filing on record for Deep Track Capital, which disclosed 55 positions worth $1.42B. Its ten largest holdings account for 43% of the portfolio.
Its largest position is Travere Therapeutics: 2,450,000 shares worth $76M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Miscellaneous and Real Estate.
- Deep Track Capital's largest Q4 2021 buy was Travere Therapeutics: 2,450,000 shares worth $76M.
- Deep Track Capital's ten largest holdings make up 43% of its $1.42B portfolio in Q4 2021.
- Deep Track Capital disclosed 55 positions in Q4 2021, its first 13F filing on record.
Based on Deep Track Capital's 13F filing for Q4 2021, filed 14 Feb 2022.